Hormonal
Chronic partial sleep restriction in humans causes metabolic dysregulation characterized by decreased insulin sensitivity, elevated glucose levels, and altered appetite hormones (decreased leptin, increased ghrelin), creating a physiological state that predisposes individuals to obesity and type 2 diabetes.
Prioritize getting 7-9 hours of quality sleep. Chronic sleep restriction (e.g., <6 hours) directly impairs your body's ability to process sugar and regulates hunger hormones to make you crave more food. Fixing sleep is a prerequisite for effective weight management, not just a passive activity.
healthy male subjects restricted to a 4-h sleep opportunity each night for six consecutive nights exhibited elevated glucose levels and decreased insulin sensitivity... Sleep restricted subjects also had a significant decrease in the rate of glucose disposal and a reduction in insulin secretion... 4 h of sleep restriction for only two consecutive nights resulted in notably reduced circulating levels of the anorectic hormone, leptin, and increased levels of the orexigenic hormone, ghrelin, along with self-reports of increased appetite
Why this rating
Based on well-controlled human clinical trials and consistent epidemiological data, though the paper notes research is 'in its infancy'.
Source
Sleep and circadian rhythms: Key components in the regulation of energy metabolism
Aaron D. Laposky et al. · FEBS Letters · 2007
DOI 10.1016/j.febslet.2007.06.079
More from this paper
- Disruption of circadian rhythms (e.g., shift work, jet lag, or genetic clock gene mutations) directly contributes to obesity, metabolic syndrome, and cardiovascular disease by desynchronizing internal physiological processes and peripheral clock genes.Good
- In rodents, chronic total sleep deprivation leads to weight loss and negative energy balance due to increased sympathetic tone and brown adipose tissue thermogenesis, whereas in humans, chronic partial sleep restriction leads to weight gain and positive energy balance due to increased appetite.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →